Colorectal cancer in adolescents and young adults with Lynch syndrome: a Danish register-based study

Jon Ambæk Durhuus, Christina Therkildsen, Thomas Kallemose, Mef Nilbert

ABSTRACT

Objective To assess clinicopathological predictors and prognosis in early-onset colorectal cancer (CRC) in Lynch syndrome with comparison to patients diagnosed from age 40 and up.

Design National, retrospective register-based case-control study.

Setting Danish national hereditary CRC register.

Participants Individuals with Lynch syndrome diagnosed with CRC from January 1950 to June 2020. The analysis was based on 215 early-onset CRCs diagnosed between 15 and 39 years of age and 574 CRCs diagnosed at age 40–88 years.

Main outcome measures Clinical and histopathological characteristics and survival. Confounding variables were analysed by Cox analysis.

Results 27.2% of the tumours in the Danish Lynch syndrome cohort were diagnosed under age 40. Disease-predisposing alterations in MLH1 and MSH2 were overrepresented in the age 15–39 cohort compared with patients diagnosed over age 40. CRCs diagnosed under age 40 showed an adverse stage distribution with 36.2% stage III–IV tumours compared with 25.8% in the over age 40 group. However, young patients diagnosed with early-stage tumours did have a significantly better prognosis compared with early-stage tumours in the older age group.

Conclusions Early-onset CRC in Lynch syndrome is primarily linked to alterations in MLH1 and MSH2 and displays an adverse stage distribution. These observations serve as a reminder of surveillance, symptom awareness and rapid diagnostic handling of CRC in young adults with Lynch syndrome.

INTRODUCTION

Colorectal cancer (CRC) incidence shows divergent trends in various age groups. In many western countries, the incidence of CRC above age 50 is decreasing, which has been attributed to the introduction of population-based screening. At the same time, incidence rates under age 50 annually increase by 1%–3% with particularly worrying rates in the youngest age group from age 18 to 40 years. In 2010, 5% of colon cancers and 9% of rectal cancers were diagnosed under age 50. Due to these increasing incidences it has been estimated that 11% of colon cancers and 22% of rectal cancers will be diagnosed under age 50 by 2030 with the largest estimated increase in the age group 20–34 years. However, paediatric CRC is rare with an estimated frequency under 1 per 1 000 000 cases.

Young age at onset is a hallmark of hereditary cancer, and at least 20% of the CRC cases are estimated to show familial patterns, and 5% carry disease-predisposing genetic variants. Under age 35–40 years, up to one-third of the cases have been reported to be linked to hereditary syndromes, such as Lynch syndrome. Lynch syndrome is caused by disease-predisposing genetic variants in the mismatch-repair (MMR) genes MLH1, MSH2, MSH6 and PMS2 and represents the most common cause of hereditary CRC. Individuals with Lynch syndrome have 40%–70% risk of CRC with a mean age at first diagnosis of 40–45 years, and 40% of the tumours are diagnosed under age 40. The increased life-time risk of CRC motivates surveillance colonoscopies, which typically include biennial examinations from age 25 years. Rational design of surveillance programmes is challenged by variable age at onset and risk...
of cancer within families, which calls for increased knowledge of predictors and characteristics of CRC under age 40 in individuals with Lynch syndrome.\textsuperscript{25}

In individuals under age 40, symptoms of CRC tend to be unspecific. Furthermore, the disease is not a first-hand diagnostic consideration, which may explain observed diagnostic delays in this group. Patients with CRC under age 40 show a predilection for tumours in the descending colon and the rectum, an over-representation of signet ring cell histology, mucinous and poor differentiation, more advanced stage at diagnosis and higher mortality rates.\textsuperscript{1, 2, 9, 12, 26-28} The clinicopathological characteristics in the early-onset group suggest distinct routes of tumour development, though the molecular underpinnings remain to be defined. Data on early-onset CRC in Lynch syndrome are scarce and better knowledge in this field could support risk-adapted surveillance.\textsuperscript{29} Motivated by the alarming increase in incidence of sporadic CRC under age 40, we defined this age as cut-off for early-onset CRC in Lynch syndrome. This also fits well with a mean age at diagnoses just above 40 in individuals with Lynch syndrome who do not undergo surveillance. We aimed to define predictors of early-onset CRC in Lynch syndrome, as well as clinicopathological characteristics and prognosis based on a national Lynch syndrome cohort.

**METHODS**

**Study population and data extraction**

This retrospective register-based case-control study was based on the national Danish Hereditary Non-polyposis Colorectal Cancer (HNPCC) register. The register contains more than 80,000 individuals with a suspected or verified risk of familial or hereditary CRC.\textsuperscript{30} All individuals with disease-predisposing MMR gene alterations were eligible for the study, which defined a cohort of 520 families in which all diagnoses were verified based on clinical charts and/or histopathology reports. We considered the first primary CRC and defined the early-onset group as CRC cases diagnosed under age 40. Two hundred and fifteen cases aged 15–39 years where found and the clinicopathological findings and survival of these groups were compared with the remaining cases diagnosed at 40–88 years of age.

Clinical data were extracted from the Danish HNPCC register on 11 June 2020 and the following variables were retrieved: MMR gene alteration (in the genes\textit{MLH1},\textit{MSH2},\textit{MSH6},\textit{PMS2} and\textit{EPCAM}), sex, date of birth, date of death, documentation for diagnostics, date of diagnosis, tumour morphology, stage and location.\textit{EPCAM} alterations can cause inactivation of the downstream\textit{MSH2} gene,\textsuperscript{31} and were pooled with\textit{MSH2} variants. The reported TNM classification was translated into clinical stage with analysis of tumour stage as well as clinical stage. Stage I included T1–T2, N0 and M0 tumours. Stage II consisted of T3–T4, N0 and M0. Stage III was T1–T4, N1-2 and M0, and stage IV included any T, any N and M1. Likewise, reports of tumours located in the ascending colon, cecum, hepatic flexure and transverse colon were altogether analysed as proximal tumours, whereas reported tumours in the sigmoid colon, splenic flexure and descending colon were considered distal tumours.

Diagnoses based only on family history (n=14) and metachronous/synchronous tumours (n=239) were excluded. Furthermore, diagnoses before 1950 were removed (n=3), leaving 789 eligible individuals for the study (figure 1). We would like to note that register studies are not subjected to ethical review according to Danish regulations. Furthermore, the manuscript has been written in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology reporting guidelines.\textsuperscript{32}

**Patient and public involvement**

Public and patient involvement was planned through the Danish HNPCC register that arranges annual patient information events and presents ongoing research projects on its web page.

**Statistical analysis**

Clinicopathological characteristics in the two study groups were initially analysed by univariate methods. Categorical variables in the two cohorts were analysed using $\chi^2$ test and differences within continuous variables were evaluated for normality assumption and calculated using Student’s t-test. Five-year survival probabilities were visualised using the Kaplan-Meier method and differences between the two cohorts were estimated adjusted using Student’s t-test.

**Flowchart of the study population. CRC, colorectal cancer; HNPCC, Hereditary Non-polyposis Colorectal Cancer.**

\begin{figure}
\centering
\includegraphics[width=\textwidth]{flowchart.png}
\caption{Flowchart of the study population. CRC, colorectal cancer; HNPCC, Hereditary Non-polyposis Colorectal Cancer.}
\end{figure}
for stage by Kaplan-Meier estimator and tested by using log-rank test. Variables that were found to be statistically significant were further analysed. Adjusted estimates were presented as hazard ratios (HR) from Cox proportional hazard models and tested by Wald test. Possible confounding factors for the Cox model included MMR gene and tumour stage. The proportion of CRC under age 40 years in the total cohort (n=789) was stratified by year of diagnostics and the ratio of CRCs diagnosed under versus over age 40 per decade is shown in a bar plot to illustrate possible time-dependent incidence. All statistical analyses were conducted using R (R Core Team (2019) V.3.6.1. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria) using the ggplot2 and survival packages. All p values were two-sided and statistical significance was reached at <0.05.

RESULTS
In the total Danish Lynch syndrome cohort, the first CRC was considered in patients diagnosed after year 1950 (N=789). The total cohort contained 447 males (56.7%) and 342 females (43.3%) from 418 different families aged 15–88 years with a mean age at diagnosis of 48.9 years. In total, 51.7% of the CRCs were diagnosed under age 50, 27.2% under age 40, 5.6% under age 30% and 1.8% under age 25. The majority (59.1%) of the tumours were located in the proximal colon. Disease-predisposing gene alterations in the cohort affected MLH1 in 33.0%, MSH2 in 39.4%, MSH6 in 22.2% and PMS2 in 5.4% (table 1).

Due to incomplete data, further analyses related to histopathological subtypes were not performed. Moreover, inadequate data were available to test if the proportion of CRC were diagnosed during surveillance more often in the 40–88 age group than in the group under age 40.

| Characteristics | Total  | 15–39  | 40–88  | P value |
|-----------------|--------|--------|--------|---------|
| Families/individuals | 418/789 | 149/215 | 350/574 | N/A     |
| Sex, male (%)    | 447 (56.7) | 124 (57.7) | 323 (56.3) | p=0.785 |
| Age at diagnosis, mean (range) | 48.9 (15–88) | 33.1 (15–39) | 54.8 (40–88) | N/A     |
| Year of diagnosis, mean (range) | 2001 (1951–2020) | 1996.5 (1953–2019) | 2002.6 (1951–2020) | N/A     |
| Age at death, mean (range) | 59.5 (25.3–96.9) | 47.3 (25.3–89.1) | 64.3 (41.0–96.9) | p<0.001* |
| Mean survival in years (range) | 12.3 (0–55.7) | 15.8 (0–55.7) | 11.0 (0–42.1) | p<0.001* |
| Disease-predisposing gene | n (%) | n (%) | n (%) | p<0.001 |
| MLH1             | 260 (33.0) | 92 (42.8) | 168 (29.3) |        |
| MSH2             | 311 (39.4) | 97 (45.1) | 214 (37.3) |        |
| MSH6             | 175 (22.2) | 20 (9.3)  | 155 (27.0) |        |
| PMS2             | 43 (5.4)   | 6 (2.8)   | 37 (6.4)   |        |
| Tumour location  |        |        |        | p=0.734 |
| Proximal colon   | 443 (59.1) | 116 (66.6) | 327 (60.0) |        |
| Distal colon     | 184 (24.6) | 53 (26.3)  | 131 (24.0) |        |
| Rectum           | 122 (16.3) | 35 (17.1)  | 87 (16.1)  |        |
| Clinical stage   |        |        |        | p=0.006 |
| I                | 132 (19.4) | 24 (13.3)  | 108 (21.6) |        |
| II               | 355 (52.1) | 91 (50.6)  | 264 (52.7) |        |
| III              | 150 (22.0) | 46 (25.6)  | 104 (20.8) |        |
| IV               | 44 (6.4)   | 19 (10.6)  | 25 (5.0)   |        |
| Tumour stage     |        |        |        | p=0.006 |
| T1               | 44 (7.4)   | 10 (6.9)   | 34 (7.5)   |        |
| T2               | 93 (15.6)  | 17 (11.7)  | 76 (16.9)  |        |
| T3               | 247 (41.4) | 49 (33.8)  | 198 (43.9) |        |
| T4               | 212 (35.6) | 69 (47.6)  | 143 (31.7) |        |

Table 1 Clinical and histopathological characteristics of first colorectal cancer diagnosis in relation to age group

Characteristics for the total cohort. Distribution and p values between under age 40 and above age 40 for characteristics, disease-predisposing gene, tumour location, clinical stage and tumour stage.

*Student’s t-test.
NA, not applicable.
Age distribution in relation to disease-predisposing MMR gene, tumour location within the bowel and tumour stage are presented in online supplemental figure S1.

Comparison between CRCs diagnosed under age 40 versus over age 40 using univariate analysis considered age at diagnosis, age at death, survival in years, sex, MMR gene alteration, tumour location, clinical stage and tumour stage (table 1). The early-onset cases (N=215) were diagnosed at age 15–39 years, and the over age 40 cases (N=574) were diagnosed at age 40–88 years. Mean age at death was 47.3 years in the age 15–39 cohort versus 64.3 in the over age 40 cohort, whereas mean survival was 15.8 years in the age 15–39 group and 11.0 years in the over age 40 group. The differences in age of death and survival could be influenced by differences in life expectancy between these cohorts. Disease-predisposing alterations in the MMR genes MLH1 (42.8% vs 29.3%) and MSH2 (45.1% vs 37.3%) were overrepresented in the age 15–39 group, whereas MSH6 alterations were overrepresented among individuals diagnosed from age 40 and up (27.0% vs 9.3%) (p<0.001). CRCs diagnosed from age 15 to 39 were associated with an adverse stage distribution with more advanced clinical tumour stage (stage III and IV, p=0.006) as well as a higher tumour stage T4 (p=0.006). Sex and tumour location did not significantly differ between the two cohorts (table 1).

The unadjusted 5-year survival analysis did not reveal differences between the groups with a 5-year overall survival probability of 82% (unadjusted log-rank p=0.86) in both groups (online supplemental figure 2). Factors that showed significant correlation in univariate analyses, that is, disease-predisposing gene and clinical stage, were included in the adjusted multivariate Cox model. Tumour stage was not included due to its interaction with clinical stage. Age group and disease-predisposing gene(s) were not significantly associated with overall survival, whereas clinical stage did predict an increased risk for death as expected with HRs of 5.06 for clinical stage III and 28.1 for clinical stage IV (table 2).

Next, we investigated differences in 5-year survival in the two age groups stratified for clinical tumour stage (online supplemental figure 3A–D). There was an increased probability of 5-year overall survival in the 15–39 age group with tumour stage II (online supplemental figure 3A) (p=0.03). Differences in survival between the age groups in tumour stage I, III and IV were insignificant and in some cases, such as stage IV, the numbers were quite low (online supplemental figure 3D). Therefore, we chose to analyse early-stage and late-stage between the age groups, where stage I and II were classified as early-stage (I+II) and stage III and IV as late-stage (III+IV) (figure 2). After adjustment for tumour stage, 5-year overall survival in early-stage tumours was 97% in the age 15–39 group and 90% in the group diagnosed over age 40 (p=0.017). The corresponding figures in late-stage tumours were 55% in the age 15–39 group and 65% in the group above age 40 (p=0.27).

In the data set from the national Danish HNPCC registry we could follow the age distribution at diagnosis of the first CRC over time (figure 3A, B). The frequency of CRCs diagnosed per decade increased in both age groups (figure 3A). However, the largest increase in numbers was observed in the group above age 40. Reported diagnoses per decade remained relatively constant in the group under age 40 during the time period 1950–1989, whereas the incidences doubled during the period 1990–2019 (figure 3A). The proportion of the two groups per decade, shows that the older group starts as the minor group, and ends up comprising 80% of diagnosed CRC in the last decade (figure 3B). The increasing number of diagnosed CRCs is influenced by an expanding number of identified Lynch syndrome families and due to surveillance programmes that have gradually been introduced for individuals with increased risk of CRC. Thus, these data need to be interpreted with caution. Our data do, however, not support an increasing proportion of CRCs in the age 15–39 group over time in the Danish Lynch syndrome cohort.

Among adolescents and young adults under age 25 we observed 14 CRCs, of which 6 were diagnosed under age 20. Clinicopathological data from these cases are summarised in online supplemental table 1. Of the 14 CRCs under age 25, data on diagnostic path were available from 9 cases, of whom 8 were diagnosed due to symptoms. Two of these individuals had concurrent ulcerative colitis, which motivated colonoscopy in the only individual diagnosed through surveillance. This subset showed a predominance for advanced T stages with 28.6% T3 and 28.6% T4 tumours, though still with a predominance for

| Characteristics | HR | 95% CI | P value |
|-----------------|----|-------|---------|
| Age of onset    |    |       |         |
| 40–88 years (reference) | — | — | — |
| 15–39 years     | 0.90 | 0.64 to 1.28 | 0.6 |

Clinical stage

| Stage (reference) | HR | 95% CI | P value |
|------------------|----|-------|---------|
| Stage I          | 1.94 | 0.86 to 4.36 | 0.11 |
| Stage II         | 5.06 | 2.25 to 11.4 | <0.001 |
| Stage III        | 28.1 | 12.3 to 64.3 | <0.001 |
| Stage IV         | 10.2 | 4.57 to 22.6 | <0.001 |

Disease-predisposing gene

| MMR gene (reference) | HR | 95% CI | P value |
|----------------------|----|-------|---------|
| MLH1                 | 1.23 | 0.53 to 2.86 | 0.6 |
| MSH2                 | 0.97 | 0.42 to 2.26 | >0.9 |
| MSH6                 | 1.39 | 0.58 to 3.33 | 0.5 |

HR, 95% CI and p value for age of onset (of first colorectal cancer), age of diagnosis, clinical stage, disease-predisposing gene and tumour stage.
clinical stage II (50.0%) and few stage III–IV tumours (online supplemental table 1).

**DISCUSSION**

Based on the national Danish Lynch syndrome cohort, we demonstrate that early-onset CRC, defined as tumours under age 40 (15–39 years), is largely driven by disease-predisposing variants in *MLH1* and *MSH2* and show a dismal clinicopathological profile with an overrepresentation of advanced tumours (T4 and stage III–IV tumours). In this age group, 36.2% of the patients were diagnosed with stage III–IV tumours compared with 25.8% in the group above age 40. Among patients diagnosed with early-stage tumours, the age 15–39 group showed significantly better survival whereas no significant difference applied to late-stage tumours. However, the over-representation of late-stage tumours in the age 15–39 group with an overall 5-year survival of 55% calls for increased awareness to support early diagnostics and thereby improved outcomes.

Our population approach with data from 215 CRC cases in the age 15–39 group and 574 CRCs diagnosed at age 40 and up, provides a robust sample size. Nevertheless, the retrospective cohort design over a long time period could introduce ascertainment bias based on more distinguishing phenotypes in the earlier years. This was indeed observed in the higher percentage of early-onset cases in the early decades (figure 3A–B). This would imply that early-onset cases may have been more frequent in the early study period and may more often represent index cases with a tendency for more advanced tumour stage. Bias may also relate to TNM stages since pathology record...
from the first half of the study period used the Dukes classification and generally had a lower number of lymph nodes identified and evaluated, which implies a less precise conversion into TNM stages. Furthermore, we did not have access to complete information on surveillance colonoscopies, which implies that we could not correct for route of diagnosis, that is, symptomatic versus during surveillance.

Compared with sporadic CRC, tumours linked to Lynch syndrome have been demonstrated to have a favourable prognosis with survival probabilities above 80% after 10 years for stage I–III tumours, which has been linked to growth patterns with strong immune reactions and a lower risk of nodal spread.35 We verify an excellent prognosis for stage I–II tumours with 5-year survival rates of 97% in the age 15–39 cohort and 90% in the above age 40 cohort. However, among patients diagnosed under age 40, 36.2% were clinical stage III–IV at diagnosis with 81.4% of the tumours being T3–T4. Whether this reflects particularly early and aggressive tumour development in these patients, suboptimal compliance to surveillance or insufficient surveillance procedures as regards to quality or colonoscopy, surveillance intervals or other factors, remains unknown. Risk modifying factors such as the specific MMR gene defects, genetic modifiers, lifestyle factors and inflammatory processes, may influence the individual risk. The observation that adolescents, young adults and patients up to age 40 frequently present with large and late-stage tumours calls for attention to surveillance procedures, adherence and potential risk factor reduction in this patient group.36 For late-stage tumours, 5-year survival rates were not significantly different at 55% in the early-onset group and 65% in the late-onset group. These figures support observations of an adverse prognosis in adolescents and young adults with non-hereditary CRC where prolonged diagnostic processes, adverse risk factor profiles and an overrepresentation of advanced disease stages have been documented.6 11 On the other hand, the significantly better outcomes with 97% 5-year survival for young patients with early-stage disease motivates early diagnostics in genetically predisposed individuals.

In Denmark, colonoscopic surveillance in Lynch syndrome is initiated from age 25, which implies that cases under this age were symptomatic, except for occasional patients surveilled due to intercurrent inflammatory bowel disease. Our study confirms that in Lynch syndrome the risk of developing CRC under age 40 is driven by disease-predisposing alterations in *MLH1* and *MSH2*, which supports risk-adapted surveillance from age 25 in *MLH1* and *MSH2* carriers and from age 30 years in *MSH6* and *PMS2* carriers.37 Tailored surveillance based on transparent risk communication is aimed at early diagnostics, patient safety and rational use of resources. In the Danish Lynch syndrome cohort, 1.8% of CRCs were diagnosed under age 25. Within this subgroup, 57.2% of the tumours were T3–T4, though only 21.3% were clinical stages III–IV (online supplemental table 1). International Lynch syndrome surveillance programmes for CRC generally include biennial colonoscopies from age 20 to 25 years.30 38 In Denmark the recommended start age for colonoscopic surveillance is 25 years, which aligns with the start age recommended within the recent European guidelines.39 The youngest cases in our cohort were aged 15 and 18 years, respectively, at diagnosis. Information regarding CRC in the teenage period in Lynch syndrome is largely based on case reports, which precludes conclusions on genetic predictors and disease causes and implies that evidence for best practise is limited.40 41 The observation of early-onset CRC in patients with concomitant inflammatory bowel disease adds to a previously suggested increased risks and lower age at onset (median 36 years) in the 1.4% of Lynch syndrome individuals that have inflammatory bowel disease with a particularly increased risk for patients with ulcerative colitis.42–47 Suppression of low-grade inflammation by non-steroidal anti-inflammatory drugs could be particularly relevant in individuals with this dual risk profile. This is supported by preclinical data on synergistic effects from MMR deficiency and inflammation with an accelerated neoplastic process demonstrated in *MSH2*-deficient mice and from clinical observations of long-lasting effects from Aspirin demonstrated in the CAPPS trial.48–51 Denmark has a high and increasing incidence of inflammatory bowel disease, which implies that the diagnostic duality, Lynch syndrome and inflammatory bowel disease, is relevant from a cancer-prevention and early diagnostics perspective.43 52

In summary, 27.2% of the CRCs diagnosed in the Danish Lynch syndrome cohort developed under age 40% and 1.8% were diagnosed under age 25. CRCs under age 40 is linked to disease-predisposing alterations in *MLH1* and *MSH2* and show an adverse risk profile with more advanced stage tumours. In contrast, Lynch syndrome patients diagnosed with stage I–II tumours under age 40, show a significantly better survival than the older age group. This underscores an unmet need for optimised clinical management to support early diagnostics in young individuals at increased risk of CRC. Furthermore, a possible link to inflammatory bowel disease is suggested in adolescents and young adults, which calls for attention to surveillance procedures and awareness of symptoms in individuals with dual risk profiles.

**CONCLUSION AND CLINICAL IMPLICATIONS**

Our investigation addresses early-onset CRC in a national Lynch syndrome cohort. We demonstrate that development of CRC in Lynch syndrome individuals under age 40 is largely driven by disease-predisposing variants in *MLH1* and *MSH2*. This age group also shows a significant overrepresentation of T4 tumours and late-stage tumours which have implications for patient survival. Though being a rare presentation, we would like to stress awareness of early-onset CRC in order to optimise patient outcome.
Ryan NAJ, Morris J, Green K, et al. Association of mismatch repair mutation with age at cancer onset in Lynch syndrome. *JAMA Oncol* 2017;3:1702–6.

Biller LH, Syngal S, Yurgelun MB. Recent advances in Lynch syndrome. *Fam Cancer* 2019;18:211–9.

Seppälä TT, Latchford A, Negoi I, et al. European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender. *Br J Surg* 2021;108:484–98.

Ahn DH, Rho JH, Tchah H, et al. Early onset of colorectal cancer in a 13-year-old girl with Lynch syndrome. *Korean J Pediatr* 2016;59:40–2.

Zajo K, Colace SI, Mouhlas D, et al. Lynch syndrome-associated colorectal cancer in a 16-year-old girl due to a de novo MSH2 mutation. *BMJ Case Rep* 2020;13:e233935.

Derikx LAAP, Smits LJT, van Vliet S, et al. Colorectal Cancer risk in patients with Lynch syndrome and Inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2017;15:454–8.

Drescher KM, Sharma P, Lynch HT. Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch syndrome patients. *Clin Dev Immunol* 2010;2010:1–13.

Lourensz K, Jones I. Considerations and management of a patient with three metachronous cancers in association with Lynch syndrome and ileal Crohn's disease: a case report. *Int J Surg Case Rep* 2015;10:73–5.

Lynch HT, Lynch JF, Lynch PM, et al. Hereditary colorectal cancer syndromes: molecular genetics, genetic counseling, diagnosis and management. *Fam Cancer* 2008;7:27–39.

McNamara KL, Aronson MD, Cohen Z. Is there a role for prophylactic colectomy in Lynch syndrome patients with inflammatory bowel disease? *Int J Colorectal Dis* 2016;31:9–13.

Minami N, Yoshino T, Nakase H. Unique endoscopic findings of colitis-associated colorectal cancer in a patient with ulcerative colitis and Lynch syndrome. *J Crohns Colitis* 2014;8:336–7.

Kohonen-Corish MRJ, Daniel JJ, te Riele H, et al. Susceptibility of Msh2-deficient mice to inflammation-associated colorectal tumors. *Cancer Res* 2002;62:2092–7.

Stidham RW, Higgins PDR. Colorectal cancer in inflammatory bowel disease. *Clin Colon Rectal Surg* 2018;31:168–78.

Sankaranarayanan R, Kumar DR, Altinoz MA, et al. Mechanisms of colorectal cancer prevention by Aspirin: A literature review and perspective on the role of COX-Dependent and -independent pathways. *Int J Mol Sci* 2020;21:9018.

Burn J, Sheth H, Elliott F, et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. *Lancet* 2020;395:1855–63.

Liu X, Goldblum JR, Zhao Z, et al. Distinct clinicohistologic features of inflammatory bowel disease-associated colorectal adenocarcinoma: in comparison with sporadic microsatellite-stable and Lynch syndrome-related colorectal adenocarcinoma. *Am J Surg Pathol* 2012;36:1228–33.